Olfactory ensheathing cells genetically modified to secrete GDNF to promote spinal cord repair

Li Cao,1 Li Liu,1,2 Zhe-Yu Chen,1 Li-Mei Wang,1 Jun-Li Ye,1,2 Hai-Yan Qiu,1,2 Chang-Lin Lu1 and and Cheng He1

1Department of Neurobiology, Second Military Medical University, Shanghai 200433 and 2Department of Pathophysiology, Qingdao Medical College of Qingdao University, Shandong 266021, China.
Li Cao and Li Liu contributed equally to the study

Correspondence to: Cheng He, Department of Neurobiology, Second Military Medical University, Shanghai 200433, China
E-mail: chenghe@online.sh.cn

Summary

Olfactory ensheathing cell (OEC) transplantation has emerged as a very promising therapy for spinal cord repair. In this study, we tested the ability of genetically modified OECs to secrete high levels of glial cell line-derived neurotrophic factor (GDNF) to promote spinal cord repair. The GDNF gene was transduced into OECs using a retroviral-based system. The engineered OECs were first characterized by their ability to express and secrete biologically active GDNF in vitro. After implantation into the spinal cord of adult rats with complete spinal cord transection, OEC survival and GDNF production were examined. The locomotor functions of animals were assessed and axon regeneration was evaluated at the morphological level. To our knowledge, we report for the first time that the genetically modified OECs are capable of producing GDNF in vivo to significantly improve recovery after spinal cord injury (SCI). This work combined the outgrowth-promoting property of OECs with the neuroprotective effects of the additionally overexpressed neurotrophic factors and opens new avenues for the treatment of SCI.

Keywords: spinal cord injury; olfactory ensheathing cell; glial cell line-derived neurotrophic factor; transplantation; gene therapy

Abbreviations: CM = conditioned medium; CSN = corticospinal neuron; CST = corticospinal tract; DMEM = Dulbecco’s modified Eagle medium; GDNF = glial cell line-derived neurotrophic factor; GFAP = glial fibrillary acidic protein; GFP = green fluorescent protein; HRP = horseradish peroxidase; LTR = long terminal repeat; NF = neurofilament; OECs = olfactory ensheathing cells; PBS = phosphate-buffered saline; RSN = rubrospinal neuron; SCI = spinal cord injury

Received August 4, 2003. Revised October 23, 2003 Accepted October 24, 2003

Introduction

Spinal cord injury (SCI) is one of the most devastating forms of trauma experienced by humans. Approximately half of the patients have complete cord injury with no preservation of voluntary motor or sensory function below the level of injury (Tator et al., 1990). Development of powerful strategies to treat SCI is still a major clinical challenge, although recent dramatic progress in cellular transplantation, gene therapy and molecular treatment has heightened the optimism about future cures for such injuries (Grill et al., 1997a, b; Giehl et al., 1997; Li et al., 1997; Rapalino et al., 1998; Jones et al., 2001; Blits et al., 2002; Schwab, 2002).

Olfactory ensheathing cells (OECs) permit growing axons from neurons of the nasal cavity olfactory mucosa to re-enter the olfactory bulb of the brain and form synapses with second-order neurons (Doucette, 1984). Recent studies have shown that implantation of rodent and human OECs appears to be one of the most promising strategies to promote long-distance regeneration in the injured spinal cord (Li et al., 1997; Barnett et al., 2000; Kato et al., 2000; Ramon-Cueto et al., 2000). Yet the number of axons that regrow and reconnect is still insufficient (Gudino-Cabrera et al., 2000).

Neurotrophic factors were originally identified as critical mediators of neuronal survival and nerve fibre outgrowth during development. The beneficial effects of neurotrophic factors on neuronal protection and repair in the CNS have been well documented (Tuszynski, 1999; Jones et al., 2001).
Although more than 30 neurotrophic factors are known, fewer than six of them have been investigated as potential treatments for lesioned spinal cords in the animal model (Schwab, 2002). Brain-derived neurotrophic factor and neurotrophin-3 have been studied extensively to find whether they have a role in promoting regeneration of spinal motor pathways (Jones et al., 2001; Liu et al., 2002; Tusznyski et al., 2003; Zhou et al., 2003). Brain-derived neurotrophic factor was reported to promote rubrospinal tract (RST) regeneration, but has limited effects on corticospinal tract (CST) regeneration (Schnell et al., 1994; Tetzlaff et al., 1994). Neurotrophin-3, which has been found to augment the growth of corticospinal axons after spinal cord injury, has been showed to promote the death of some corticospinal neurons (Giehl et al., 2001). More recent studies also show that removal of NT-3 or blocking TrkC activity could enhance myelination of Schwann cells, which is known to be very important for functional recovery (Chan et al., 2001; Cosgaya et al., 2002). The glial cell line-derived neurotrophic factor (GDNF), originally identified as a trophic factor for midbrain dopaminergic neurons (Lin et al., 1993), has been found to be the most potent trophic factor for motoneurons (Henderson et al., 1994; Li et al., 1995; Oppenheim et al., 1995). Fibroblasts expressing GDNF were able to directly promote axon elongation of primary cultured cortical neurons (Paratcha et al., 2003). In a similar culture system, cortical neurons growing on a monolayer of fibroblasts expressing brain-derived neurotrophic factor were characterized by a great number of shorter and more branching neurites, suggesting that GDNF may have a more potent effect in stimulating axonal growth in these cells (Paratcha et al., 2003). Furthermore, GDNF was able to induce motor axon outgrowth across the surrounding white matter in the organotypic spinal cord culture model (Ho et al., 2000). When applied into the spinal cord, GDNF was able to exert a trophic effect on corticospinal nerves and promote long-term survival after axotomy (Giehl et al., 1997). Moreover, GDNF has recently been shown to exert behavioural and anatomical neuroprotection following SCI (Watabe et al., 2000; Cheng et al., 2002). Injections and pumps can be used to deliver neurotrophic factors to the lesion site. However, these methods do not achieve long-term, localized, high-dose neurotrophic factor delivery. An alternative approach that achieves long-term and site-specific delivery of neurotrophic factors to the injured spinal cord is ex vivo gene therapy (Tusznyski, 1997). Schwann cells, fibroblasts and intercostal nerve grafts genetically engineered to express neurotrophic factors have been reported (Grill et al., 1997; Menei et al., 1998; Tusznyski et al., 1998; Blits et al., 1999, 2000; Liu et al., 1999a, b; Blesch et al., 2001). These studies described increased sprouting of various axonal populations but, in most cases, the majority of regenerating axons were rerouted around the transplant and few fibres were seen distal to the site of injury.

Implants of OECs may be better for neurotrophic factor delivery since this may be helpful for regenerating axons to re-enter the distal part of the spinal cord (Li et al., 1997; Ramon-Cueto et al., 2000) and is advantageous over the use of genetically engineered fibroblasts, which are non-CNS in origin and may become tumorigenic. The feasibility of transplanting genetically modified OECs into the intact and injured spinal cord was extensively described by Ruitenberg et al. (Ruitenberg et al., 2002). Therefore, upgrading of the growth-promoting properties of OEC by having them secrete additional neurotrophic factors may be a valuable strategy for promoting spinal cord repair (Blits et al., 2002; Ruitenberg et al., 2002), since limited neurotrophic factor expression of OECs has been reported (Boruch et al., 2001; Woodhall et al., 2001).

In the present study, we tested the ability of genetically modified OECs to secrete a high level of GDNF in order to promote spinal cord repair. The GDNF gene was transduced into OECs using a retroviral system. The engineered OECs were first characterized by their ability to express and secrete biologically active GDNF in vitro. After implantation into the spinal cord of adult rats with complete spinal cord transection, OEC survival and GDNF production were examined. The locomotor functions of animals were assessed, and axon regeneration was evaluated at the morphological level. To our knowledge, we report for the first time that the genetically modified OECs are capable of producing GDNF in vivo to significantly improve recovery after SCI.

Materials and methods

Primary culture and purification of OECs

Primary olfactory bulb cultures were set up from adult Sprague–Dawley rats (2.5 months old). The modified protocol of Ramon-Cueto and colleagues (Ramon-Cueto et al., 1998) was used. Briefly, the olfactory nerve layer was peeled away from the rest of the olfactory bulb, then dissociated with 0.25% trypsin and 0.03% collagenase and incubated at 37°C for 30 min. The cells were then washed with D/F 12±10% fetal bovine serum and 20 g/ml of M forskolin (Sigma). The purity of the cultured OECs was determined by comparing the number of Hoechst-labelled nuclei with the number of p-75 NGFR immunoreactive cells under a microscope.

Retroviral preparation and infection of OECs

The cDNA encoding rat preproGDNF was isolated by using the RT-PCR method with total RNA extracted from rat brain. Specific
Fig. 1 Structure of double-copy retroviral vector pN2A-GDNF. The original Moloney murine leukaemia virus-based retroviral vector pN2A contains a GDNF gene in the U3 region of the 3'-LTR. 'neo' is a G418/neomycin resistant gene. 'Double copy' indicates that in the infected cell the transduced gene could be duplicated and transferred to the 5'-LTR (asterisk). Placement of the foreign gene outside the retroviral transcriptional unit, eliminating or at least reducing the negative effects of the retroviral transcriptional unit, was able to improve the expression of the foreign gene (Hantzopoulos et al., 1989).

Characterization of GDNF OECs

Primary cultures of adult rat normal OECs and GDNF OECs were fixed for 10 min with 4% paraformaldehyde. After washing in PBS and blocking with 1% bovine serum albumin for 30 min, the cultures were incubated overnight at 4°C with the rabbit polyclonal anti-human GDNF antibody (1/200; Promega), anti-p75NGFR rabbit antibody (5 pg/ml, Santa Cruz Biotechnology), monoclonal mouse anti-glial fibrillary acidic protein (GFAP) (1 : 1000; Sigma) and anti-S-100 mouse antibody (1 : 2000; Sigma) diluted in PBS containing 1% bovine serum albumin. The next day the cultures were first washed in PBS and then incubated for 40 min at 37°C with fluorescein isothiocyanate-labelled secondary antibodies (Promega). They were then washed and examined with an Olympus BX-50 fluorescence microscope.

Assay of GDNF production

The amount of GDNF secreted by GDNF OECs was measured by enzyme-linked immunosorbent assay (ELISA) using the GDNF Emax ImmunoAssay System (Promega). According to the manufacturer's instructions, the ELISA plates (96 wells) were coated with an anti-GDNF monoclonal antibody (pH 8.2) overnight at 4–8°C. Plates were then blocked for 1 h at room temperature with blocking buffer. GDNF standards ranging from 0 to 100 pg/ml were prepared using recombinant GDNF. Conditioned medium (CM) was obtained using 2 × 10⁶ cells in 2 ml medium, but with only 1% fetal bovine serum for 24 h, then added to the wells (100 μl) undiluted or diluted 1 : 10 or 1 : 100. Samples and standards were incubated at room temperature for 6 h on a shaker. The plate was then incubated sequentially with chicken anti-human GDNF polyclonal antibody overnight at 4°C, horseradish peroxidase (HRP)-conjugated anti-chicken antibody (1 : 5000) at room temperature for 2 h, and the enzyme substrate tetramethylbenzidine for 15 min at room temperature. PBS was used to wash the plates after each step. The enzyme reaction was stopped by adding 100 ml of 1 M phosphoric acid per well and the absorbance was measured at 450 nm. Sample values were calculated from the standard curve in the linear range.

The biological activity of the secreted GDNF was tested using a PC12 cell line, which stably expresses GDNF receptor GFRα1 and Ret (Chen et al., 2001). Briefly, 2 × 10⁵ PC12-GFRα-Ret cells were added to each well of a 24-well plate (Costar) that had been coated with poly-l-lysine. After attachment, the cells were exposed to CM from OECs or GDNF OECs. PBS was used as negative control and 100 ng/ml GDNF was the positive control. GDNF was prepared as previously described (Chen et al., 2000). Five days later, the effect of GDNF on cell differentiation was determined. Cells possessing one or more neurites of a length more than twice the diameter of the cell body were scored as positive. Each value is the mean ± SEM sampled from three independent experiments.

Hoechst labelling of OECs

When cells reached confluence, monolayers of purified OECs or GDNF OECs were incubated at 37°C in 1.5 μg/ml of the nuclear fluorochrome bisbenzimide (Hoechst 33342; Sigma) for 15 min. After several washes in Dulbecco's modified Eagle medium (DMEM), cells were trypsinized and collected for transplantation.

Surgical procedures

Animal care and use followed recommended NIH guidelines. Female adult Sprague-Dawley rats were anaesthetized with 2% pentobarbital sodium (0.2 ml/kg) intraperitoneally. Lamincotome was performed to expose the dorsal surface of the T₈-₉ segment, followed by a transection at T₄ using microscissors. The distal stump was carefully lifted up, allowing verification of complete transection. Rats then received stereotaxic injections into four sites of the midline of both cord stumps (ventral funiculus, grey commissure, dorsal CST, gracile fasciculus) at 1 mm from the transaction site (Ramon-Cueto et al., 1998) using sterile glass needles. In total, 41 animals were operated: (i) eight animals received a transection with no grafted OECs, and each site received 0.5 μl DMEM; (ii) 15 received a graft of normal OECs, each site...
receiving 0.5 μl OEC suspension containing about 50 000 cells; and (iii) 18 received a graft of GDNF OECs, each site receiving 0.5 μl cell suspension containing about 50 000 cells. Postoperatively, rats were kept at 22±2°C on highly absorbent bedding, injected with cefazolin sodium (40 mg/day) for up to 1 week, and received bladder expression twice daily until normal function returned.

RT-PCR analysis
Two months after cell transplantation, animals of the OEC or GDNF OEC group were euthanized with a lethal dose of pentobarbital sodium and T7-0 spinal cord tissue was collected. Total RNA was isolated from the tissue using TRizol (Gibco BRL) and the RNA concentration was measured photometrically. After RNA extraction, the samples were digested with RNase-free DNase I, and cDNA was synthesized using a Dmniscript TM PT kit (Qiagen). For PCR, specific primers (forward, 5'-AATATGCCCGAAGATTATCC-3'; reverse, 5'-GTATTAGCGGAATGCTTTTCT-3') were designed to amplify GDNF cDNA to yield 466 bp amplified products. To quantify the RT-PCR, β-actin (primers: forward, 5'-AAGATTTGCCACCACACTTTCTAC-3'; reverse, 5'-CACGTTGGGCCTTAGGGTT-3') was co-amplified with GDNF. Forty picomoles of each primer and 1 μg DNA were used for PCR, which was carried out in a programmable heating block using cycles consisting of denaturation at 95°C for 1 min followed by annealing at 55°C for 1 min and DNA extension at 72°C for 1 min. After 30 cycles of PCR, samples were electrophoresed on 1.5% agarose gel. Gels were stained with ethidium bromide and photographed under ultraviolet light.

Retrograde tracing with HRP
Twelve animals (three controls, four from the OEC and six from the GDNF OEC group) were used for HRP retrograde tracing. Eight weeks after surgery, an aqueous suspension of 30% HRP (Sigma; RZ...
and 2% dimethyl sulphoxide (Sigma) was injected bilaterally three or four segments caudal to the transplant to avoid diffusion of HRP into the transplant. After injection, the surgical exposure was closed and the animals were maintained for 36 h before being perfused by buffered 1% paraformaldehyde and 1.25% glutaraldehyde. The brain and spinal cord were removed and stored in 20% sucrose in 0.1 M PBS at 4°C overnight. Then the sensory motor cortex in the forebrain and the magnocellular portion of the red nucleus in the midbrain were cut transversely and serially at 30 μm. Every third section in the red nucleus or cortex was collected and stained with tetramethylbenzidine (Sigma) and hydrogen peroxide according to the method of Mesulam (Mesulam, 1978). After counterstaining with neutral red, the sections were observed under a light microscope. The distal spinal cord including the transected area was cryosectioned sagittally to ensure the injection was confined and that there was no spread of dye to the transplant. Animals that did not measure up to this criterion were eliminated from the study.

For identification of neurons in the red nucleus and cortex, the caudalmost section through the nucleus magnocellularis and sensory motor cortex where HRP-labelled neurons could be observed was designated as the first section for analysis. The numbers of HRP-labelled and neutral red-labelled rubrospinal neurons (RSNs) and corticospinal neurons (CSNs) on both sites were counted separately using a digitizing tablet and PC-based software (Metamorph). The criterion for a CSN was an HRP-filled pyramidal shape >4 μm in diameter. For the RSN, only neurons with a clearly visible nucleus were counted.

Antegrade tracing with biotinylated dextran amine
Antegrade tracing of CST fibres from the motor cortex was performed following Ramon-Cueto et al. (2000). Briefly, animals were anesthetized and two holes were drilled in the cranium to expose both sensorimotor cortices. A 10% solution of biotinylated dextran amine (BDA; molecular weight 10 000; Molecular Probes) was injected bilaterally in eight sites of each sensorimotor cortex (0.5 ml/site) to cover the entire hindlimb region. Eighteen days later, rats were killed and spinal sections were incubated with fluorescein-conjugated streptavidin to visualize BDA-containing corticospinal axons. To quantify CST fibres we followed a method described previously (Blits et al., 2000). To quantify the number of CST fibres
in the animals that survived for 8 weeks, the centre of each lesion (between the proximal and distal scar) was identified microscopically and determined as point 0. From this point, fibre counting was performed on the sagittal sections and at 2.5 and 4.5 mm proximal and distal to the centre of the lesion.

Immunohistochemistry
Rats were perfused with 4% paraformaldehyde in 0.1 M ice-cold phosphate buffer. The spinal cord was removed, postfixed for 5 h and placed in 30% sucrose/PBS before preparing 30 μm sagittal cryosections. Hoechst-labelled OECs were visualized with a fluorescent microscope equipped with a 365 nm excitation filter and a 420 nm emission filter. For immunofluorescence, sections were permeabilized and blocked with 0.3% Triton X-100/10% normal goat serum in 0.1 M PBS for 15 min. Primary antibodies were then applied to the sections overnight at 4°C. Each section was double-labelled with mouse monoclonal immunoglobulin G against neurofilaments (Sigma; 1 : 200) and anti-p75NGFR. The following day, sections were incubated with fluorescein isothiocyanate-conjugated goat anti-mouse and rhodamine-conjugated goat anti-rabbit (Promega) secondary antibodies. Slides were washed, mounted, and examined by Olympus fluorescent microscopy.

Neurofilament (NF) immunohistostaining was quantitatively determined in 3 mm wide strips of spinal tissue through the lesion centre. Slides were viewed and photographed with an Olympus photo microscope (BX70). The photographs were digitized with a video image analysis system (Metamorph) in conjunction with a computer. After background correction, the grey levels of each slide were automatically detected. Then the mean of grey levels for all slides from each animal were obtained and statistical analysis was performed.

Functional recovery
Functional tests were performed before operation and 2 h, 3 days and 1, 2, 3, 4, 5, 6, 7 and 8 weeks after operation. Locomotor activity was evaluated using the open-field walking scoring system. One animal at a time was allowed to move freely inside a circular plastic tray (90 cm diameter, 24 cm wall height) for 5 min. Behavioural recovery was scored according to the BBB (Basso, Beattie, Bresnahan) scale (Basso et al., 1996), which is composed of 21 different criteria of the movement of the hind limb from complete paralysis to complete mobility. As a second test for hind limb function, animals were subjected to an inclined plane test (Rivlin and Tator, 1977). The maximum angle at which the animal could maintain a stable position for 5 s on the inclined plane was recorded. Before each evaluation, we carefully examined the rats for perineal infection, wounds in the hind limbs, and tail and foot autophagia.

Results
Characterization of GDNF OECs
The GDNF OECs in primary cultures, which had a spindle-like morphology with two or three processes or a flat appearance (Franceschini and Barnett, 1996; Li et al., 1998; Gudino-Cabrera et al., 2000; Wewetzer et al., 2002), displayed S-100 immunoreactivity (Fig. 2A and B). Most GFP-positive OECs are immunoreactive for p75NGFR (blue). Additional p75NGFR staining outside the confines of GFP labelling could be due to the Schwann cells that have invaded the spinal cord, as suggested by Ruitenberge et al. (2002). Scale bar = 150 μm. This figure can be viewed in colour as supplementary material at Brain Online.
Fig. 7 NF immunostaining through the spinal cord lesion 8 weeks after injury. (A) Haematoxylin and eosin staining demonstrated that spinal cord transection resulted in an obvious traverse scar at the T8 lesion epicentres (arrow) and neuronal necrosis, reactive gliosis and cavitation in adjacent rostral and caudal regions. (B) GFAP immunochemistry shows glial scar (arrow) in spinal cord lesion. (C, D) In control animals, NF immunofluorescence at the lesion site (outlined in C) displayed mostly scattered profiles, and many NF-immunoreactive fibres were stopped at the host–scar interface (arrows). (E, F) In the normal OEC group, elongated NF-positive axons (arrows) were present throughout the lesion (outlined in E). (G, H) In the GDNF OEC group, a dramatically increased amount of NF-positive fibres (arrows) was found in the lesion site (outlined in G); some of them were derived from the invaded dorsal root (asterisk). The axonal profiles within the centre of the lesion site had a variety of orientations. Scale bars = 100 μm in A, C, E, G; 25 μm in B, D, F, H. This figure can be viewed in colour as supplementary material at Brain Online.
ing for GDNF was much stronger in GDNF OECs than in normal OECs (Fig. 2E and F).

**Ex vivo GDNF secretion and biological effect**

The amount of GDNF secreted by GDNF OECs was determined by ELISA with detection sensitivity to 31.2 pg/ml of GDNF. GDNF production by uninfected OECs was estimated to be 95 pg/ml per 10^6 cells, whereas GDNF OECs produced an average of 25 ng GDNF/10^6 cells/day (Fig. 3).

The biological activity of the secreted GDNF was examined using PC12-GFRα-Ret cells. After 72 h of culture in CM from normal OECs, 5.4 ± 1.87% of cells differentiated. However, in CM from GDNF OECs, cell differentiation was six-fold greater than that of normal OECs (Fig. 4). This bioassay confirmed that GDNF secreted from GDNF OECs was biologically active and capable of promoting PC12-GFRα-Ret cell differentiation.

**Transgenic gene expression of OECs in vivo**

Eight weeks after surgery, RT-PCR was used to measure the mRNA level of GDNF in the injured spinal cord (Fig. 5). In injured spinal cord injected with GDNF OECs, significantly
higher levels of GDNF mRNA expression were detected compared with that in the spinal cord of rats injected with normal OECs. This result demonstrated that *ex vivo* transduction of OECs with retrovectors resulted in persistently increased GDNF expression *in vivo*, up to at least 2 months after implantation.

To further confirm the expression of the transgene and the location of OECs in the lesion, OECs were infected with the recombinant retrovirus containing green fluorescent protein (GFP), then implanted in the lesion of spinal cord. As shown in Fig. 6, 2 months after implantation, GFP-labelled OECs were visualized as a dense mass of elongated, brightly fluorescent cells extending from the lesion site. Most GFP-positive implants were immunoreactive for p75NGFR. These results confirmed that the implanted OECs were capable of surviving in the injured spinal cord for at least 2 months after implantation. The OECs were gathered in the lesion gap, which was surrounded by an intensively GFAP-positive border of reactive astrocytes. We could not find OECs across the astrocytic barrier into the spinal cord. These

Fig. 9 Photomicrographs showing HRP retrograde tracing of CSN (A, C, E, G) and RSN (B, D, F, H) 8 weeks after thoracic transection. The dark purple-staining cells are HRP-positive. (A, B) Sham-operated animal. (C, D) DMEM group. (E, F) OEC group. (G, H) GDNF OEC group. In the DMEM group (control), few HRP-labelled neurons were observed in the CSN or RSN. In animals receiving OECs only, a few labelled cells were observed. Numerous HRP-labelled neurons were found in the GDNF OEC group. Scale bar = 200 μm. This figure can be viewed in colour as supplementary material at Brain Online.
results are in good agreement with previous report by Ruitenberg and colleagues (Ruitenberg et al., 2002).

**Axonal regeneration**

Spinal cord transection lesion was characterized by an obvious traverse scar at the T8 lesion epicentres and neuronal necrosis, reactive gliosis and cavitation in adjacent rostral and caudal regions (Fig. 7A and B). In control animals, 2 months after lesion only scattered NF-positive fibres were found in the central scar and many NF-immunoreactive fibres were stopped at the host–scar interface (Fig. 7C and D). As shown in Fig. 7E and F, elongated NF-positive axons are present throughout the lesion in normal OEC group. Dramatically increased amounts of NF-positive fibres were found in the lesion site in the GDNF OEC group, and some of them were derived from the invaded dorsal root (Fig. 7G and H). High-magnification microscopy showed numerous NF-positive axons growing through the lesion, often in close association with implanted OECs or GDNF OECs (Fig. 8). In the GDNF OEC group, NF-positive axons were often found in bundles. Statistical analysis revealed significantly higher grey levels of NF immunoactivity in animals receiving GDNF OECs than in those receiving normal OECs.

Figure 9 shows RSN and CSN labelling after injections of HRP into the low thoracic and upper lumbar region. HRP retrograde staining showed that most labelled RSN were located in the ventral–lateral portion of the magnocellular nucleus of the red nucleus (Fig. 9B, D, F, H). Neurons in the cortex (Fig. 9A, C, E, G) were smaller than in the RSN. As shown in Fig. 10, the number of HRP-labelled RSN and CSN were counted in all groups of animals. On average, in normal animals, ~386 and ~2737 neurons were labelled on both sides of the RSN and CSN, respectively. After thoracic transection, few HRP-labelled RSN or CSN were detected in the DMEM group. With treatment of normal OECs, a few cells (RSN, 50; CSN, 355) labelled with HRP were detected. OEC transplantation may have provided a permissive environment that allowed a small percentage of axotomized neurons to regenerate into the caudal spinal cord (P < 0.01 versus DMEM group). The highest regeneration ratio was in the GDNF OEC group (approximately 97 in RSN and 776 in CSN were labelled with HRP). These numbers were significantly higher than those in the normal OEC group (P < 0.01).

To further confirm the axonal regeneration, antegrade tracing experiments were performed. Figure 11 shows the images for BDA-traced corticospinal axons 8 weeks after spinal cord injury. In the control group, the transected CST showed little regeneration response in the segment rostral to the lesion centre. However, in the normal OEC group a few CST fibres were found to have formed termination bulbs and some fibres had grown through the lesion and reached the segment distal to the lesion centre. Quantitative analysis revealed that more BDA-traced CST fibres were found in the segment near the injury side in the GDNF OEC group. Interestingly, in a distal segment 4.5 mm away from the lesion centre, no significant differences were found between the OEC and GDNF OEC groups (Fig. 12).

**Behavioural assessment**

Figure 13 shows the behavioural results during the 8-week assessment period for each group of animals. All injured rats manifested complete hind limb paralysis immediately after injury. The BBB scores were in the range of 0–2 in the control animals. Following transplantation of the OECs, hind limb functional recovery increased gradually; 8 weeks after transplantation, all 15 animals displayed BBB scores greater than that achieved by any of the eight controls (P < 0.01).
Five of the 15 experimental animals from the OEC group could support their body weight on their hind limbs; the other 10 animals had ankle, knee and hip movements in one or both legs but did not obviously bear weight. The GDNF OEC group regained more functional recovery than the normal OEC group 8 weeks after transplantation ($P < 0.01$); 10 of the 18 rats treated with GDNF OECs could walk in a coordinated manner.

Differences in score on the inclined plane test among the three groups were also significant. From 2 weeks after operation, rats in the OEC group began to show more functional recovery than those in the control group ($P < 0.05$) and at 5 weeks after implantation animals in the GDNF OEC group had a higher score than those in the OEC group ($P < 0.05$).

**Discussion**
Combining transplantation and gene therapy is perhaps one of the most powerful strategies to promote CNS repair. As implantation of OECs in the injured spinal cord has been reported to promote long-distance regeneration and func-
tional recovery following SCI (Li et al., 1997; Ramon-Cueto et al., 2000), there is much interest in upgrading OECs to enhance the regenerative properties of these cells. Recently, researchers have begun to transfect OECs to express fluorescent markers for tracing experiments (Ruitenberg et al., 2002) or to use transgenic animals expressing a xenogeneic protein as a source for modified OECs (Imaizumi et al., 2000). In the present study, OECs were genetically modified to overexpress exogenous neurotrophic factor and were transplanted into the transected spinal cord.

Ex vivo gene therapy is a valuable approach to the achievement of long-term and site-specific delivery of therapeutic agents in the CNS. Both retroviral and adenovirus vectors have been widely used for gene transfer. Retrovectors integrate with high efficiency and contain no viral genes so they may mediate long-term expression and avoid host cellular immune responses (Robbins et al., 1998). In the present study, high levels of transgenic GDNF mRNA could be detected even 2 months after implantation. Tracing the GFP OECs confirmed that the implanted, genetically modified OECs were capable of surviving and expressing the foreign gene in the spinal cord lesion. The sustained high-level expression of GDNF in OEC implants allows the possibility of manipulating the growth-promoting properties of OECs and the microenvironment at the lesion site not only during the acute but also during the chronic phase following injury. Retrovectors are limited by the viral LTR sequence, which may interfere with the expression of various gene cassettes. No changes in morphology and expression of general cell marker proteins were detected after transduction of OECs by retroviral vectors in this study. Following ex vivo gene transfer, implants of transduced OECs into the site of a spinal cord lesion were p75NGFR-positive and displayed typical bipolar morphology, suggesting that gene transfer with retroviral pN2A-GDNF vectors did not interfere with normal cell functioning.

GDNF was originally identified as a potent trophic factor for midbrain dopaminergic neurons (Lin et al., 1993; Beck et al., 1995; Tomac et al., 1995). It was subsequently found that GDNF also strongly supports the survival of motoneurons both in vitro and in vivo (Henderson et al., 1994; Li et al., 1995; Oppenheim et al., 1995; Yan et al., 1995; Houenou et al., 1996). When applied into the spinal cord, GDNF exerts a trophic effect on corticospinal neurons and promotes their long-term survival after axotomy (Giehl et al., 1997). In the present study, we demonstrate that treatment with OECs with a modified GDNF gene could stimulate an increase in the regeneration of corticospinal or rubrospinal axons in adult rats after spinal cord transection compared with treatment.

![Fig. 12](http://brain.oxfordjournals.org/)

**Fig. 12** Quantitative comparison of CST regrowth in the spared grey matter of the transected spinal cord 8 weeks after implantation. To compensate for variations in actual tracing efficiency by the cortical BDA injections, the fibre number counted 4.5 mm proximal from the centre of the lesion was set to 100% and all data were calculated as relative percentages. In the control group, few CST fibres were observed in the distal spinal cord. In the normal OEC group, a few CST fibres had grown through the lesion and reached the segment distal to the lesion centre. In the GDNF OEC group, however, more CST regrowth was found in the segment near the injury side. *P < 0.05, **P < 0.01 versus DMEM group; ^P < 0.05, ~P < 0.01 versus OEC group. ANOVA test followed by least significant difference test, n = 5.

![Fig. 13](http://brain.oxfordjournals.org/)

**Fig. 13** Functional analysis of hindlimb movements following SCI among animal groups, using the BBB behavioural assessment (top) and the inclined plane (IP) test (bottom) *P < 0.05, **P < 0.01 versus control group; ~P < 0.05, ~P < 0.01 versus OEC group. ANOVA test followed by least significant difference test, n = 8–18.
with normal OECs. The HRP retrograde labelling studies clearly demonstrated that injured axons had indeed regenerated through the transection site. Numerous HRP-labelled neurons were detected 8 weeks after SCI in the GDNF OEC group. However, in the normal OEC group, less than half of the HRP-labelled neurons were detected. BDA antegrade tracing experiments confirmed that more CST fibres had grown through the lesion and reached the segment distal to the lesion centre in the GDNF OEC group than in the normal OEC group. NF immunohistochemical labelling also showed large number of fibres in the lesioned spinal cord following GDNF OEC injections. These results suggest that GDNF ex vivo gene delivery might enhance the growth-promoting properties of OECs after SCI. There are several possible explanations for this phenomenon. First, GDNF elicits a chemotropic effect, directing the growth of axons to regions with the highest concentration of growth factor. Secondly, GDNF may increase the survival ratio of RSN and CSN after axotomy, which results in an increased number of regenerated corticospinal or rubrospinal fibres. Moreover, recent studies have also shown that cultured OECs express GDNF receptor GFRα1 (Woodhall et al., 2001); therefore, high levels of GDNF secreted from GDNF OECs may have trophic effects on themselves.

The locomotor functions of animals were evaluated using the inclined plane method of Rivlin and BBB scale. The BBB scoring system differs from other locomotor scoring systems in several respects. First, the score is not a summation of component behaviours. Each BBB score requires fulfilment of a unique set of criteria. Secondly, the scores encompass many behavioural traits and represent a detailed characterization of rat locomotor function. Thirdly, the scores are based on observations of rat recovery from SCI. The ordering of the scores assumes progressive recovery and that each recovery stage represents better locomotion than the preceding stage (Basso et al., 1996). Using the BBB scale and the inclined plane method, we demonstrated a progressive recovery over time among three groups. The functional recovery in the GDNF OEC group showed statistically significant improvements compared with the normal OEC group. This result is in accordance with the morphological experiments. Significant improvements of locomotor function were also achieved in the GDNF OEC and normal OEC groups compared with the control group. The enhanced recovery of function in the GDNF OEC group may not have been mainly due to the enhanced outgrowth of a still very limited number of nerve fibres, according to our retrograde and antegrade tracing results. After spinal cord transection, rats from the control group always had severe tissue loss next to the transection centre. A positive correlation of the increased tissue sparing with higher locomotor scores after SCI has been reported previously (Basso et al., 1996). It is conceivable that the transplanted OECs have a beneficial effect on tissue sparing, as shown by other investigators in recent publications (Takami et al., 2002; Plant et al., 2003). Moreover, GDNF secreted by the OEC may also counteract the tissue loss, as the GDNF administration was reported to increase tissue sparing in a contusion model (Cheng et al., 2002). Furthermore, GDNF secreted by the OEC may have stimulated the repair or survival of spinal motor neurons, which may have contributed to the functional recovery (Watabe et al., 2000; Cheng et al., 2002).

In summary, the present study shows that the growth-promoting properties of OECs were significantly improved when these cells were genetically modified to secrete an increased level of GDNF. Genetic engineering of OECs opens up new possibilities for future clinical applications in SCI.

Note added in proof
As this manuscript was under revision Ruitenberg et al. (2003) published their paper which addresses the point of the effect of genetically modified OECs on tissue sparing. Their results may help to support the notion that the behavioural effect observed in the present study could be partly explained in this way.

Acknowledgements
We thank Professor Xuan Bao for her helpful suggestions and valuable comments. We thank Dr Karin Beloussow and Dr Xu Zhang for critically reading the manuscript. The pN2A vector was kindly provided by Professor Baoyu Guo. This work was supported by Shanghai Biotech and Drug R & D (004319203), National Natural Science Foundation 30325022 and the National Basic Research Program (G199905400) of China.

References
Boruch AV, Conners JJ, Pipitone M, Deadwyler G, Storer PD, Devries GH,

Chan JR, Cosgaya JM, Wu YJ, Shooter EM. Neurotrophins are key mediators of the myelination program in the peripheral nervous system. Proc Natl Acad Sci USA 2001; 98: 14661–8.


Cosgaya JM, Chan JR, Shooter EM. The neurotrophin receptor p75NTR as a positive modulator of myelination. Science 2002; 298: 1245–8.


Hantzopoulos PA, Sullenger BA, Unger S, Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the gial cell line. Mol Cell Biol 1986; 6: 3353–63.


